Prof. Alasdair Coles (Cambridge University Hospitals, United Kingdom) discussed why induction therapy is the preferred principle over treatment escalation. “I have to admit that there is no perfect induction therapy in humans”, he mentioned at the beginning of his talk.
The ideal induction therapy for an autoimmune disease is one “short sharp shock” of treatment with a restricted period of adverse effects, leading to long-lasting disease-specific immunological tolerance. This approach leaves the remaining immune system competent to fight infections and the patients free of infectious diseases risk.
“How close are we to this ideal model in the management of MS?” Prof. Coles asked. “There are only 3 therapies which come close to what we might consider induction therapies of MS: autologous haematopoietic stem cell therapy (aHSCT), alemtuzumab, and cladribine. I want to make a point that not all high-efficacy therapies are induction therapies by the prov...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« The maternal perspective: when to stop/resume treatment and risks for progression Next Article
Tumour Mutation Score Is a Better Predictor than Tmb »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.